<DOC>
	<DOC>NCT01923584</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of EPI-743 in patients with Parkinson's disease.</brief_summary>
	<brief_title>A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>1. Diagnosis of Parkinson's disease 2. Age 40 75 3. Ambulatory with or without assistance 4. Hoehn and Yahr Scale score of 1 3 5. Patient able to consent and comply with protocol requirements 6. Abstention from use of Coenzyme Q10, vitamin E, Azilect and Idebenone two weeks prior to enrollment and during course of treatment with EPI743 1. Allergy to EPI743 or sesame oil 2. Allergy to vitamin E 3. Clinical history of bleeding or abnormal baseline PT/PTT 4. Diagnosis of any other neurologic disease 5. Malignancy within past two years 6. Pregnant or plans to become pregnant 7. Concomitant ophthalmologic disease 8. History of stroke 9. History of brain surgery 10. Inability to undergo MRI scan or MRS 11. Hepatic insufficiency with LFTs greater than two times upper limit of normal 12. Renal insufficiency requiring dialysis 13. End stage cardiac failure 14. Fat malabsorption syndromes precluding drug absorption 15. Use of anticoagulant medications, azilect</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>